Invokana Efficacious in Older Population with Uncontrolled T2DM

Janssen announced new results from a Phase 3 clinical study evaluating Invokana (canagliflozin) at the 2014 American Diabetes Association Scientific Sessions.

DIA3010 was a randomized, double-blind study evaluating Invokana in patients aged 55–80 years with type 2 diabetes not controlled on current antihyperglycemic medications. Study results showed that after 104 weeks, Invokana 100mg and 300mg provided greater reductions in HbA1c relative to placebo: -0.49% (95% CI: -0.65, -0.32) and -0.60% (95% CI -0.77, -0.44).

RELATED: Diabetes Treatments Chart

Greater improvements in the following secondary endpoints were also seen with Invokana 100mg and 300mg, respectively, compared to placebo:

  • The percent of patients reaching the A1C goal level of <7%: 15.6% (95% CI: 7.2, 24.0) and 21.7% (95% CI: 13.0, 30.3)
  • Body weight reduction: -2.3% (95% CI: -3.1, -1.6) and -3.2% (95% CI: -4.0, -2.4)
  • Fasting plasma glucose reduction: -21.4mg/dL (95% CI: -28.5, -14.2) and -23.4mg/dL (95% CI: -30.6, -16.2)
  • Systolic blood pressure reduction: -5.8mmHg (95% CI: -8.0, -3.5 and -7.5mmHg (95% CI: -9.8, -5.2)
  • Increased levels of HDL-C: 3.6% (95% CI: 0.4, 6.9) and 4.8% (95% CI: 1.5, 8.1)

For more information visit Invokana.com.

Loading links....